TrialInternational journal of hematology2024

Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.

Souichi Shiratori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.